Madrigal Pharmaceuticals (MDGL) Financials: History & Chart

Madrigal Pharmaceuticals, Inc.(MDGL)

Biotechnology · West Conshohocken, PA

$500.48+6.86 (+1.39%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

West Conshohocken, PA

915 employees

www.madrigalpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: William J. Sibold

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.28B	364.25M	311.34M	321.08M	287.27M	212.80M	137.25M	103.32M	62.17M
Cost of Goods Sold	109.42M	40.01M	26.85M	24.45M	18.12M	9.06M	4.51M	3.44M	2.15M
Gross Profit	1.17B	324.25M	284.49M	296.63M	269.15M	203.74M	132.74M	99.88M	60.02M
Gross Profit Margin	91.5%	89.0%	91.4%	92.4%	93.7%	95.7%	96.7%	96.7%	96.5%
Total Operating Expenses	1.50B	380.55M	377.21M	356.24M	383.12M	250.94M	212.05M	166.87M	176.33M
Research & Development	490.14M	91.18M	108.69M	116.27M	174.00M	54.08M	44.17M	25.65M	68.74M
Selling, General & Administrative	1.01B	289.38M	268.52M	239.98M	209.12M	196.86M	167.88M	141.22M	107.58M
Operating Income (EBIT)	-322.62M	-56.31M	-92.72M	-59.61M	-113.97M	-47.20M	-79.31M	-67.00M	-116.30M
Operating Margin	-25.1%	-15.5%	-29.8%	-18.6%	-39.7%	-22.2%	-57.8%	-64.8%	-187.1%
Income Before Tax (EBT)	-325.10M	-57.94M	-94.39M	-58.58M	-114.19M	-42.28M	-73.24M	-59.42M	-106.96M
Interest Income	35.11M	7.10M	8.24M	9.46M	10.31M	8.23M	9.37M	11.08M	13.02M
Interest Expense	15.63M	-7.94M	7.82M	8.30M	7.45M	3.26M	3.30M	3.50M	3.68M
Other Income/Expense	-2.48M	-1.63M	-1.67M	1.03M	-215K	4.92M	6.07M	7.58M	9.34M
Net Income	-325.10M	-57.94M	-94.39M	-58.58M	-114.19M	-42.28M	-73.24M	-59.42M	-106.96M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-25.3%	-15.9%	-30.3%	-18.2%	-39.8%	-19.9%	-53.4%	-57.5%	-172.0%
EBITDA	-321.10M	-55.93M	-92.34M	-59.22M	-113.62M	-46.83M	-78.93M	-66.63M	-116.01M
EBITDA Margin	-25.0%	-15.4%	-29.7%	-18.4%	-39.6%	-22.0%	-57.5%	-64.5%	-186.6%
Depreciation & Amortization	1.52M	381K	386K	392K	358K	377K	379K	363K	298K
EPS Basic	-12.89	-1.99	-3.25	-2.57	-5.08	-1.90	-3.32	-2.71	-4.92
EPS Diluted	-12.89	-1.99	-3.25	-2.57	-5.08	-1.90	-3.32	-2.71	-4.92
Weighted Average Basic Shares	23.07M	23.07M	29.03M	22.43M	22.48M	22.21M	22.09M	21.93M	21.75M
Weighted Average Diluted Shares	23.07M	23.07M	29.03M	22.43M	22.48M	22.21M	22.09M	21.93M	21.75M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	958.40M	180.13M	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold	56.15M	6.23M	0.00	0.00	0.00	471K	112K	96K
Gross Profit	902.25M	173.90M	0.00	0.00	0.00	-471K	-112K	-96K
Gross Profit Margin	94.1%	96.5%	N/A	N/A	N/A	N/A	N/A	N/A
Total Operating Expenses	1.20B	671.77M	380.50M	293.57M	242.48M	205.85M	94.86M	40.36M
Research & Development	388.52M	236.72M	272.35M	245.44M	205.16M	184.81M	72.32M	25.39M
Selling, General & Administrative	813.83M	435.06M	108.15M	48.13M	37.32M	21.86M	22.65M	14.97M
Operating Income (EBIT)	-300.10M	-497.88M	-380.50M	-293.57M	-242.48M	-206.32M	-94.97M	-40.46M
Operating Margin	-31.3%	-276.4%	N/A	N/A	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-288.28M	-465.89M	-373.63M	-295.35M	-241.85M	-202.24M	-83.95M	-32.81M
Interest Income	37.36M	46.65M	19.58M	2.19M	363K	4.33M	11.02M	7.67M
Interest Expense	22.31M	14.67M	12.71M	3.96M	N/A	N/A	N/A	N/A
Other Income/Expense	11.81M	31.98M	6.87M	-1.78M	636K	4.08M	11.02M	7.64M
Net Income	-288.28M	-465.89M	-373.63M	-295.35M	-241.85M	-202.24M	-83.95M	-32.81M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-30.1%	-258.6%	N/A	N/A	N/A	N/A	N/A	N/A
EBITDA	-298.59M	-496.78M	-379.97M	-293.10M	-242.08M	-205.85M	-94.86M	-40.36M
EBITDA Margin	-31.2%	-275.8%	N/A	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	1.51M	1.10M	527K	467K	405K	471K	112K	96K
EPS Basic	-12.85	-21.90	-19.99	-17.23	-14.63	-13.09	-4.73	-2.22
EPS Diluted	-12.85	-21.90	-19.99	-17.23	-14.63	-13.09	-4.73	-2.22
Weighted Average Basic Shares	22.43M	21.27M	18.69M	17.14M	16.54M	15.45M	15.39M	14.80M
Weighted Average Diluted Shares	22.43M	21.27M	18.69M	17.14M	16.54M	15.45M	15.39M	14.80M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.